Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 12:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,928 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Head and neck Clear all
Active, not recruiting No phase listed Observational

Depression and Adherence in Head and Neck Cancer

NCT00498875
View directory record Official record
Conditions
Oropharyngeal Cancer, Head and Neck Cancer
Interventions
Questionnaire, Depression Intervention
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

NCT03234712
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-321
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
14
States / cities
Springdale, Arkansas • Los Angeles, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Head and Neck Cancer

NCT00404339
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
mutant p53 peptide pulsed dendritic cell vaccine, tetanus toxoid helper peptide, adjuvant therapy
Biological · Procedure
Lead sponsor
Robert Ferris
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer

NCT03032250
View directory record Official record
Conditions
Caregiver, Malignant Head and Neck Neoplasm, Paranasal Sinus Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage I Hypopharyngeal Squamous Cell Carcinoma, Stage I Laryngeal Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Hypopharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Squamous Cell Carcinoma, Stage II Lip and Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma, Stage III Lip and Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Laryngeal Squamous Cell Carcinoma, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Stage IVA Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Hypopharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Hypopharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal SCC, Recurrent Paranasal Sinus Squamous Cell Carcinoma
Interventions
Communication Intervention, Watch video, Module completion of the Prepare to Care kit, Quality-of-Life Assessment, Survey Administration, Salivary cortisol collection
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Phase 2 Interventional

Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer

NCT00448552
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
capecitabine, oxaliplatin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Not applicable Interventional

Biobehavioral Efficacy of the Semi-Elevated Side-Lying Position

NCT04942106
View directory record Official record
Conditions
Feeding, Bottle, Infant, Premature, Diseases, Behavior, Infant
Interventions
Arm 1 - Side-lying position followed by Supine position, Arm 2 - Supine position followed by Side-lying position
Other
Lead sponsor
Boston College
Other
Eligibility
Up to 2 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Sep 30, 2026, 12:12 PM EDT
Recruiting Phase 1 Interventional

FAPI-74 PET/CT in Adults With Fibrosis

NCT06413355
View directory record Official record
Conditions
Fibrosis (Morphologic Abnormality)
Interventions
[F-18]-FAPI-74
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 30, 2026, 12:12 PM EDT
Recruiting Phase 2 Interventional

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

NCT07094685
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ivonescimab, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
Procedure · Biological
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Phase 2 Interventional Results available

BIBW 2992 (Afatinib) in Head & Neck Cancer

NCT00514943
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
BIBW 2992, Cetuximab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
18
States / cities
Stanford, California • Chicago, Illinois • Harvey, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 30, 2026, 12:12 PM EDT
Terminated Phase 1Phase 2 Interventional

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

NCT04278144
View directory record Official record
Conditions
HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer
Interventions
BDC-1001, Nivolumab
Drug
Lead sponsor
Bolt Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 30, 2026, 12:12 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Rebuilding Inter-limb Transfer in Cervical SCI

NCT06440538
View directory record Official record
Conditions
Cervical Spinal Cord Injury
Interventions
PCMS + Contralateral Motor Training, PCMS + Rest, Sham PCMS + Contralateral Motor Training
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Phase 2 Interventional

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00006471
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Fenretinide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 30, 2026, 12:12 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Regional Anesthesia Block in Fibula Free Flap Reconstruction

NCT03906838
View directory record Official record
Conditions
Anesthesia, Local, Surgery, Opioid Use, Pain, Postoperative, Head and Neck Neoplasms
Interventions
Ropivacaine injection
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 30, 2026, 12:12 PM EDT
Completed No phase listed Observational

PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients

NCT03342378
View directory record Official record
Conditions
Squamous Cell Carcinoma, Oropharynx Cancer
Interventions
Intensity modulated radiotherapy (IMRT), PET-MRI
Radiation · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Phase 1 Interventional

Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer

NCT01668849
View directory record Official record
Conditions
Head and Neck Cancer, Oral Mucositis
Interventions
Grape extract, Lortab, Fentanyl patch, mouthwash
Dietary Supplement · Drug
Lead sponsor
University of Louisville
Other
Eligibility
20 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 30, 2026, 12:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626
View directory record Official record
Conditions
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
Drug · Combination Product
Lead sponsor
Marengo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Sacramento, California • Celebration, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

NCT03126110
View directory record Official record
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01876, Nivolumab, Ipilimumab
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 30, 2026, 12:12 PM EDT
Recruiting Not applicable Interventional

Pro-2-Cool Pivotal Trial II

NCT06929923
View directory record Official record
Conditions
Concussion, Mild
Interventions
Pro2Cool Device, Sham Cooling Garment Device
Device
Lead sponsor
TecTraum Inc.
Industry
Eligibility
13 Years to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Ann Arbor, Michigan • Akron, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Phase 1Phase 2 Interventional

Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer

NCT02422979
View directory record Official record
Conditions
Recurrent Head and Neck Cancer
Interventions
PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2, PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
Combination Product
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Phase 1 Interventional Results available

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

NCT00691210
View directory record Official record
Conditions
Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
Vorinostat, Niacinamide, Etoposide
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Sep 30, 2026, 12:12 PM EDT
Terminated Not applicable Interventional

Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer

NCT04110249
View directory record Official record
Conditions
Head and Neck Carcinoma, Head and Neck Lymph Node, Head and Neck Squamous Cell Carcinoma, Laryngeal Neoplasm, Radiation Therapy Recipient
Interventions
Photoacoustic Imaging, Transcutaneous Acupoint Electrical Stimulation
Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Sep 30, 2026, 12:12 PM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

NCT01192815
View directory record Official record
Conditions
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
erlotinib hydrochloride, intensity-modulated radiation therapy, pharmacogenomic studies, gene expression analysis, 3-dimensional conformal radiation therapy, biopsy, pharmacological study, laboratory biomarker analysis, questionnaire administration, enzyme-linked immunosorbent assay, polymorphism analysis
Drug · Radiation · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 30, 2026, 12:12 PM EDT
Terminated Not applicable Interventional Results available

Venous Sinus Stenting To Treat Intractable Pulsatile Tinnitus Caused By Venous Sinus Stenosis

NCT02734576
View directory record Official record
Conditions
Tinnitus, Pulsatile Tinnitus, Venous Sinus Stenosis, Dural Sinus Stenosis
Interventions
Venous Sinus Stenting with the Precise Pro Stent
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Sep 30, 2026, 12:12 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

NCT02207439
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Nelfinavir (Viracept®) 1250 mg, Chemoradiation
Drug · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Sep 30, 2026, 12:12 PM EDT